Description
Lactobacillus rhamnosus (LGG®) has been shown to or may:
- Reduce the incidence of eczema and food allergies in infants.
- Dairy free.
Clinical benefits:
- LGG® assists in reducing the incidence of eczema and allergies in high risk infants.
- LGG® may increase the transforming anti-inflammatory growth factor (TGF-B2) in breast milk. TGF-B2 is a key immunoregulatory anti-inflammatory factor that inhibits IgE synthesis.
- LGG® may reduce eczema associated symptoms such as itching and sleeplessness.
- LGG® has been shown to relieve and treat diarrhoea.
- Ultra Flora LGG® contains a high strength and extensively trialled probiotic strain with supportive evidence.
- LGG® has been shown to resist acid, bile and pancreatin digestion allowing survival through the digestive tract for colonisation.
- LGG® is a registered trademark of Chr. Hansen A/S.
| Each capsule contains: |
|
| Lactobacillus rhamnosus (LGG®) | 10 billion CFU (organisms) |
LGG® is a registered trademark of Chr. Hansen A/S.
Free from animal products, corn, dairy protein, lactose, eggs, gluten, wheat, nuts, yeast, soy protein and salt. Free from artificial colours, flavours and preservatives.
- If diarrhoea persists for more than 6 hours in infants under 6 months, 12 hours in children under 3 years, 24 hours in children aged 3-6 years or 48 hours in adults and children over 6 years - seek medical advice.
- Always read the label. Follow the directions for use.
- If symptoms persist, consult your healthcare professional.
TGA Listed product with Aust L 329597.
Download TGA Public Summary for TGA published information including excipients, which are listed under 'Other Ingredients'.